This handout is for high-risk nste-acs (cath ≤24 h). Your care team identified this based on: grace >140 in nste-acs context — early-invasive class i per acc/aha 2025.
Other reasons your team may use this plan: dynamic st depression ≥0.5 mm or transient st elevation or deep t-wave inversion (high-risk feature, acc/aha 2025); refractory angina despite max medical therapy (class i emergent → ≤2 h consideration); hemodynamic instability (sbp <90, hypoperfusion) or sustained vt/vf in nste-acs.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| aspirin | 162-325 mg load → 81 mg | PO chewed | load once → 81 mg daily lifelong | Universal — ACC/AHA 2025 Class I; ISIS-2 23% mortality reduction |
| ticagrelor | 180 mg load → 90 mg BID | PO | BID × 12 mo standard DAPT | PLATO PMID 19717846 + ISAR-REACT 5 PMID 31475799 — preferred upstream of anatomy in high-risk; ACC/AHA 2025 Class I |
| clopidogrel | 600 mg load → 75 mg | PO | daily × 12 mo | Alternative for HBR or on chronic OAC (AUGUSTUS / ENTRUST-AF PCI); ACC/AHA 2025 Class IIa |
| unfractionated_heparin | 60 U/kg bolus (max 4000) → 12 U/kg/h infusion | IV | continuous, aPTT 1.5-2× control | ACC/AHA 2025 Class I default for invasive ≤24 h; reversible; renal-friendly |
| enoxaparin | 1 mg/kg SC q12h (1 mg/kg q24h if CrCl 15-30) | SC | q12h until 24 h pre-cath then switch to UFH | ESSENCE PMID 11519503; switch to UFH at PCI per ACC/AHA 2025 |
| atorvastatin | 80 mg | PO | once daily | PROVE-IT PMID 15007110 — start day 0 high-intensity per ACC/AHA 2025 Class I |
Plan: High-risk NSTE-ACS upfront triple antithrombotic load (ASA + P2Y12 + UFH/enoxaparin) — ACC/AHA 2025 Class I; ≤24 h cath
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cardiac rehab Class I, full 5-pillar the four foundational heart-failure medications, lipid recheck 4-8 wks per IMPROVE-IT, DAPT plan 12 mo standard or de-escalation per TWILIGHT/MASTER DAPT if HBR
Guideline: 2025 ACC/AHA Guideline for ACS (Rao); ESC 2023 NSTE-ACS Guideline (Byrne, PMID 37622670)